checkpoint inhibitors

A Triple Threat Against Cancer

A three-in-one approach combining immune checkpoint inhibition, tumor microenvironment targeting and chemotherapy drugs could help tackle difficult-to-treat tumors.

China Approves Tyvyt For Hodgkin’s Lymphoma

Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody, was co-discovered by Innovent and Adimab and jointly developed by Innovent and Eli Lilly in China.

Putting The Brakes On Myasthenia Gravis

Targeting immune checkpoint proteins could slow the progress of myasthenia gravis, a chronic autoimmune disorder that causes serious weakening of the muscles.

CStone Pharma Completes US$260 Million Series B Funding Round

The funds raised will primarily be used for clinical development of CS1001 and other clinical stage assets, as well as attract top industry talents.

Prolonged Immune Activation Changes Behavior In Mice

Scientists in Japan have demonstrated that the prolonged activation of immune cells affects the production of neurotransmitters in the brain, leading to behavioral changes.

Cancer Immunotherapy For Man’s Best Friend

Scientists in Japan have developed a new therapeutic antibody to treat malignant cancers in dogs.

[INFOGRAPHIC] What You Need To Know About Immunotherapy

Our immune system protects us against a host of infections, but it can also be trained to seek out and destroy cancer.

Celgene Buys The Rights To BeiGene’s Checkpoint Inhibitor

BeiGene will acquire Celgene's commercial operations in China and exclusive license to Celgene's China cancer commercial portfolio.

Tessa Therapeutics Completes Acquisition of Euchloe Bio

Tessa Therapeutics has fully acquired Euchloe Bio, a biotech company focused on developing and commercializing therapeutic antibodies.

Tasuku Honjo Wins 2016 Keio Medical Science Prize

Honjo was recognized for his discovery of PD-1, a negative regulator of immune responses, as well as his subsequent work in the field of immunotherapy.